Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Lowell L. Hart

Ribociclib With Letrozole vs Letrozole Alone in Elderly Patients With Hormone Receptor-Positive, HER2-negative Breast Cancer in the Randomized MONALEESA-2 Trial

Breast Cancer Research and Treatment

Cancer Research

Oncology

2017

English

Related publications

TBCRC 002: A Phase II, Randomized, Open-Label Trial of Preoperative Letrozole With or Without Bevacizumab in Postmenopausal Women With Newly Diagnosed Stage 2/3 Hormone Receptor-Positive and HER2-negative Breast Cancer

Breast Cancer Research

Cancer Research

Oncology

2020

English

Palbociclib With Letrozole in Postmenopausal Women With ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial

English

Cost-Effectiveness of Palbociclib Plus Letrozole Versus Letrozole Alone as a First-Line Treatment in Women With Oestrogen Receptor-Positive, HER2-negative, Advanced Breast Cancer. Revised Results for the Swiss Health Care Setting

Breast Cancer Research and Treatment

Cancer Research

Oncology

2017

English

Is Letrozole Needed for Controlled Ovarian Stimulation in Patients With Estrogen Receptor-Positive Breast Cancer?

Gynecological Endocrinology

English

Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide as Primary Systemic Treatment in Elderly Breast Cancer Patients

Journal of Clinical Oncology

English

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Clinical Cancer Research

Cancer Research

Oncology

2019

English

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial

Journal of Clinical Oncology

English

BCT Score Predicts Chemotherapy Benefit in Asian Patients With Hormone Receptor-Positive, HER2-negative, Lymph Node-Negative Breast Cancer

PLoS ONE

Multidisciplinary

2018

English

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Geburtshilfe und Frauenheilkunde

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Lowell L. Hart

Ribociclib With Letrozole vs Letrozole Alone in Elderly Patients With Hormone Receptor-Positive, HER2-negative Breast Cancer in the Randomized MONALEESA-2 Trial

Related publications

TBCRC 002: A Phase II, Randomized, Open-Label Trial of Preoperative Letrozole With or Without Bevacizumab in Postmenopausal Women With Newly Diagnosed Stage 2/3 Hormone Receptor-Positive and HER2-negative Breast Cancer

Palbociclib With Letrozole in Postmenopausal Women With ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial

Cost-Effectiveness of Palbociclib Plus Letrozole Versus Letrozole Alone as a First-Line Treatment in Women With Oestrogen Receptor-Positive, HER2-negative, Advanced Breast Cancer. Revised Results for the Swiss Health Care Setting

Is Letrozole Needed for Controlled Ovarian Stimulation in Patients With Estrogen Receptor-Positive Breast Cancer?

Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide as Primary Systemic Treatment in Elderly Breast Cancer Patients

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial

BCT Score Predicts Chemotherapy Benefit in Asian Patients With Hormone Receptor-Positive, HER2-negative, Lymph Node-Negative Breast Cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer